BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III

Trial Profile

BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2015

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-III
  • Sponsors BIOTRONIK
  • Most Recent Events

    • 30 May 2013 Primary outcomes reported at EuroPCR, according to a Biotronik media release. Outcomes also reported in the media release.
    • 30 May 2013 Status changed from active, no longer recruiting to completed, baseed on information in a Biotronik media release.
    • 30 May 2013 Primary endpoint 'Target-lesion-failure-rate at 12 months' has been met, as reported in a Biotronik media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top